Ad26 EBOV vaccine - Crucell

Drug Profile

Ad26 EBOV vaccine - Crucell

Alternative Names: Ad26 EBOV vaccine - Crucell/NIH; Ad26 EBOV vaccine - NIH/Crucell; Ad26-ZEBOV - Crucell/NIH; Ad26-ZEBOV - NIH/Crucell; Ad26.ZEBOV - Crucell/NIH; Ad26.ZEBOV - NIH/Crucell; Ebola virus vaccine - Crucell/NIH; Ebola virus vaccine - NIH/Crucell

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Crucell; National Institutes of Health (USA)
  • Developer Bavarian Nordic; Crucell; National Institute of Allergy and Infectious Diseases; National Institutes of Health (USA)
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 19 Jan 2018 Crucell completes phase-II clinical trials in Ebola virus infections (Prevention) in France and United Kingdom (IM) (NCT02416453)
  • 01 Jan 2018 Janssen and NIAID completes a phase I trial in Healthy volunteers in USA (NCT02860650)
  • 29 Sep 2017 Johnson and Johnson receives a grant from Biomedical Advanced Research and Development Authority for Ad26 EBOV vaccine development in Ebola virus infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top